United States - English - NLM (National Library of Medicine)

american regent, inc. - zinc sulfate heptahydrate (unii: n57ji2k7wp) (zinc cation - unii:13s1s8sf37), cupric sulfate (unii: lrx7aj16dt) (cupric cation - unii:8cbv67279l), manganese sulfate (unii: w00lys4t26) (manganese cation (2+) - unii:h6ep7w5457), chromic chloride (unii: kb1pcr9dmw) (chromic cation - unii:x1n4508kf1) - zinc cation 22 mg in 1 ml - this formulation is indicated for use as a supplement to intravenous solutions given for tpn. administration of the solution in tpn solutions helps to maintain plasma levels of zinc, copper, manganese, and chromium and to prevent depletion of endogenous stores of these trace elements and subsequent deficiency symptoms. multitrace ® - 4 concentrate should not be given undiluted by direct injection into a peripheral vein because of the potential of infusion phlebitis.

United States - English - NLM (National Library of Medicine)

american regent, inc. - zinc sulfate heptahydrate (unii: n57ji2k7wp) (zinc cation - unii:13s1s8sf37), cupric sulfate (unii: lrx7aj16dt) (cupric cation - unii:8cbv67279l), manganese sulfate (unii: w00lys4t26) (manganese cation (2+) - unii:h6ep7w5457), chromic chloride (unii: kb1pcr9dmw) (chromic cation - unii:x1n4508kf1) - zinc cation 4.39 mg in 1 ml - this formulation is indicated for use as a supplement to intravenous solutions given for tpn for children up to 11 years of age. administration of the solution in tpn solutions helps to maintain plasma levels of zinc, copper, manganese, and chromium and to prevent depletion of endogenous stores of these trace elements and subsequent deficiency symptoms. multitrace ® - 4 pediatric should not be given undiluted by direct injection into a peripheral vein because of the potential of infusion phlebitis.

United States - English - NLM (National Library of Medicine)

american regent, inc. - zinc sulfate heptahydrate (unii: n57ji2k7wp) (zinc cation - unii:13s1s8sf37), cupric sulfate (unii: lrx7aj16dt) (cupric cation - unii:8cbv67279l), manganese sulfate (unii: w00lys4t26) (manganese cation (2+) - unii:h6ep7w5457), chromic chloride (unii: kb1pcr9dmw) (chromic cation - unii:x1n4508kf1) - zinc cation 2.2 mg in 1 ml - this formulation is indicated for use as a supplement to intravenous solutions given for tpn for children up to 11 years of age. administration of the solution in tpn solutions helps to maintain plasma levels of zinc, copper, manganese, and chromium and to prevent depletion of endogenous stores of these trace elements and subsequent deficiency symptoms. trace elements injection 4, usp pediatric should not be given undiluted by direct injection into a peripheral vein because of the potential of infusion phlebitis.

United States - English - NLM (National Library of Medicine)

american regent, inc. - zinc sulfate heptahydrate (unii: n57ji2k7wp) (zinc cation - unii:13s1s8sf37), cupric sulfate (unii: lrx7aj16dt) (cupric cation - unii:8cbv67279l), manganese sulfate (unii: w00lys4t26) (manganese cation (2+) - unii:h6ep7w5457), chromic chloride (unii: kb1pcr9dmw) (chromic cation - unii:x1n4508kf1) - zinc cation 4.39 mg in 1 ml - this formulation is indicated for use as a supplement to intravenous solutions given for tpn. administration of the solution in tpn solutions helps to maintain plasma levels of zinc, copper, manganese, and chromium and to prevent depletion of endogenous stores of these trace elements and subsequent deficiency symptoms. multitrace ® - 4 should not be given undiluted by direct injection into a peripheral vein because of the potential of infusion phlebitis. warnings: copper and manganese are eliminated via the bile. in patients with severe liver dysfunction and/or biliary tract obstruction, decreasing or omitting copper and manganese supplements entirely may be necessary. this product contains aluminum that may be toxic. aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum. research indicate

United States - English - NLM (National Library of Medicine)

american regent, inc. - zinc sulfate heptahydrate (unii: n57ji2k7wp) (zinc cation - unii:13s1s8sf37), cupric sulfate (unii: lrx7aj16dt) (cupric cation - unii:8cbv67279l), manganese sulfate (unii: w00lys4t26) (manganese cation (2+) - unii:h6ep7w5457), chromic chloride (unii: kb1pcr9dmw) (chromic cation - unii:x1n4508kf1), selenious acid (unii: f6a27p4q4r) (selenious acid - unii:f6a27p4q4r) - zinc cation 4.39 mg in 1 ml - this formulation is indicated for use as a supplement to intravenous solutions given for tpn. administration of the solution in tpn solutions helps to maintain plasma levels of zinc, copper, manganese, selenium and chromium and to prevent depletion of endogenous stores of these trace elements and subsequent deficiency symptoms. multitrace ® - 5 should not be given undiluted by direct injection into a peripheral vein because of the potential of infusion phlebitis.

United States - English - NLM (National Library of Medicine)

american regent, inc. - zinc sulfate heptahydrate (unii: n57ji2k7wp) (zinc cation - unii:13s1s8sf37), cupric sulfate (unii: lrx7aj16dt) (cupric cation - unii:8cbv67279l), manganese sulfate (unii: w00lys4t26) (manganese cation (2+) - unii:h6ep7w5457), chromic chloride (unii: kb1pcr9dmw) (chromic cation - unii:x1n4508kf1), selenious acid (unii: f6a27p4q4r) (selenious acid - unii:f6a27p4q4r) - zinc cation 22 mg in 1 ml - this formulation is indicated for use as a supplement to intravenous solutions given for tpn. administration of the solution in tpn solutions helps to maintain plasma levels of zinc, copper, manganese, selenium and chromium and to prevent depletion of endogenous stores of these trace elements and subsequent deficiency symptoms. multitrace® - 5 concentrate should not be given undiluted by direct injection into a peripheral vein because of the potential of infusion phlebitis.

United States - English - NLM (National Library of Medicine)

rising pharma holdings, inc. - cevimeline hydrochloride (unii: p81q6v85np) (cevimeline - unii:k9v0cdq56e) - cevimeline hydrochloride anhydrous 30 mg - cevimeline is indicated for the treatment of symptoms of dry mouth in patients with sjögren’s syndrome. cevimeline is contraindicated in patients with uncontrolled asthma, known hypersensitivity to cevimeline, and when miosis is undesirable, e.g., in acute iritis and in narrow-angle (angle-closure) glaucoma.

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - ziprasidone hydrochloride (unii: 216x081oru) (ziprasidone - unii:6uka5vej6x) - ziprasidone 80 mg - ziprasidone hydrochloride capsule is an atypical antipsychotic. in choosing among treatments, prescribers should be aware of the capacity of ziprasidone hydrochloride capsule to prolong the qt interval and may consider the use of other drugs first (5.2) ziprasidone hydrochloride capsule is indicated as an oral formulation for the treatment of schizophrenia. (1.1) adults: efficacy was established in 4 to 6 week trials and one maintenance trial in adult patients with schizophrenia  (14.1) because of ziprasidone's dose-related prolongation of the qt interval and the known association of fatal arrhythmias with qt prolongation by some other drugs, ziprasidone is contraindicated: - in patients with a known history of qt prolongation (including congenital long qt syndrome) - in patients with recent acute myocardial infarction - in patients with uncompensated heart failure pharmacokinetic/pharmacodynamic studies between ziprasidone and other drugs that prolong the qt interval have not been performed. an additive eff

United States - English - NLM (National Library of Medicine)

novel laboratories, inc. - cevimeline hydrochloride (unii: p81q6v85np) (cevimeline - unii:k9v0cdq56e) - cevimeline hydrochloride anhydrous 30 mg - cevimeline is indicated for the treatment of symptoms of dry mouth in patients with sjÖgren's syndrome. cevimeline is contraindicated in patients with uncontrolled asthma, known hypersensitivity to cevimeline, and when miosis is undesirable, e.g., in acute iritis and in narrow-angle (angle-closure) glaucoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - doxorubicin hydrochloride, quantity: 2 mg/ml - injection, concentrated - excipient ingredients: hydrogenated soy phosphatidylcholine; histidine; hydrochloric acid; ammonium sulfate; cholesterol; water for injections; sodium hydroxide; sodium methoxy peg-40-carbonyl-distearoylphosphatidylethanolamine; sucrose - indications: for the treatment of: (1) advanced epithelial ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. (2) aids-related kaposi's sarcoma (ks) in patients with low cd4 counts (<200 lymphocytes/cubic mm) and extensive mucocutaneous or visceral disease. as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and doxorubicin (or other anthracycline). indications as at 29 february 2008: caelyx, as monotherapy, is indicated for the treatment of metastatic breast cancer. caelyx is also indicated for the treatment of: advanced epithelial ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. aids-related kaposi's sarcoma (ks) in patients with low cd4 counts (<200 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. caelyx may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and doxorubicin (or other anthracycline). caelyx is also indicated, in combination with bortezomib, for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or who are unsuitable for bone marrow transplant.